Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(50%)
Results Posted
100%(1 trials)

Phase Distribution

Ph phase_1
2
50%
Ph not_applicable
1
25%

Phase Distribution

2

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(3)
Completed(1)

Detailed Status

Active, not recruiting2
Completed1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 12 (66.7%)
N/A1 (33.3%)

Trials by Status

completed125%
not_yet_recruiting125%
active_not_recruiting250%

Recent Activity

2 active trials
Showing 4 of 4
active_not_recruitingphase_1

Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies

NCT03233139
completedphase_1

A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors

NCT05407675
active_not_recruiting

Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients

NCT06269133
not_yet_recruitingnot_applicable

Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC

NCT06607926

Clinical Trials (4)

Showing 4 of 4 trials
NCT03233139Phase 1

Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies

Active Not Recruiting
NCT05407675Phase 1

A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors

Completed
NCT06269133

Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients

Active Not Recruiting
NCT06607926Not Applicable

Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC

Not Yet Recruiting

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4